Arcutis Biotherapeutics (ARQT) is in focus after reporting Q1 2026 revenue of US$105.4 million, a narrowed net loss of US$11.3 million, positive operating cash flow, and reaffirmed full year revenue guidance.

The stock closed at US$20.66 after the results, with a 1-day share price return of -14.52% and a year to date share price return of -28.76%. However, the 1-year total shareholder return is 52.87%, which suggests recent momentum has faded after a strong prior run.

If Arcutis's recent volatility has you looking across healthcare, this could be a useful moment to review other dermatology and biotech peers, or widen the search to 18 top founder-led companies

With Q1 revenue at US$105.4 million, a narrowed US$11.3 million loss, positive operating cash flow, and shares sitting well below analyst price targets, is Arcutis a mispriced growth story, or is the market already baking in what comes next?

Most Popular Narrative: 48.3% Undervalued

Against the last close at $20.66, the leading narrative on Arcutis points to a fair value of $39.99, implying a wide gap that investors are watching closely.

It is almost impossible to obtain a drug label from the FDA for pediatric use, this topical non steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.

Curious what kind of revenue trajectory and profit margins sit behind that near 50% discount claim, and how one dermatology drug underpins the entire valuation story.

According to Coward_Nutlick, the narrative assumes a sizeable addressable market for dermatology conditions, focused promotion to a limited pool of specialists, and a shift to positive earnings supported by cash flow.

The fair value estimate of $39.99 also reflects a specific discount rate of 6.89% that is applied to future cash flows, together with an assumed profit margin profile that differs from Arcutis's current loss making status.

While the narrative sees Arcutis as undervalued against this framework, readers should remember that such valuations rely heavily on the assumptions used around sales growth, profitability, and potential corporate activity.

Result: Fair Value of $39.99 (UNDERVALUED)

However, there are clear risks here, including any slowdown in ZORYVE adoption or setbacks on profitability and cash flow, which would challenge the current undervalued thesis.

Next Steps

Mixed signals on value and risk so far, so if this story interests you, act while the data is fresh and weigh both sides using the 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist now so you are not the one hearing about the next opportunity after it moves.

• Spot potential turnaround stories early by checking out 25 elite penny stocks with strong financials.
• Zero in on companies that combine quality with a price that still looks appealing using the 51 high quality undervalued stocks.
• Prioritise financial resilience by scanning companies through the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.